Both external and internal advisory committees have been established in order to optimize the SKCCC's success and to provide comprehensive, expert direction for our research activities. The Director seeks external advice to guide the development and direction of the SKCCC from a variety of sources, including the leadership of the University and Hospital, ad hoc consultants, and an External Advisory Board. Several internal advisory committees assist the Cancer Center in strategic and program planning, resource allocation, and identifying new initiatives and opportunities. The governance of the SKCCC is aimed at two major objectives: 1) maximizing the use of Cancer Center resources (human and physical) to achieve research goals;and 2) creating an efficient, effective, responsive and collegial enterprise. These committee include: 1) Executive Committee;2) Research Council;3) Protocol Review and Monitoring Committee 4) Safety Monitoring Committee;5) Laboratory Shared Resources Committee and 6) Clinical Research Operations Committee. The External Advisory Board (EAB) is composed of national leaders representing major areas of cancer research from preeminent institutions other than Johns Hopkins. This Advisory Board has played a critical role in the evaluation of scientific programs as well as assessment of the programmatic structure of this Cancer Center. Members of this Advisory Board have also been generous of their time in providing individual consultations in specific areas of their expertise.
| Zarif, Jelani C; Chalfin, Heather J; Pierorazio, Phillip M et al. (2018) Characterization of the Macrophage Infiltrate in a Case of Xanthogranulomatous Pyelonephritis. J Clin Urol 11:226-228 |
| Rowe, Steven P; Luber, Brandon; Makell, Monique et al. (2018) From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting. Mol Oncol 12:1661-1672 |
| Martin, Allison M; Nirschl, Christopher J; Polanczyk, Magda J et al. (2018) PD-L1 expression in medulloblastoma: an evaluation by subgroup. Oncotarget 9:19177-19191 |
| Yeruva, Sri Lakshmi Hyndavi; Javadi, Mehrbod Som; Stearns, Vered (2018) Complete Response to Single-agent Palbociclib in Metastatic Breast Cancer: A Case Report. Clin Breast Cancer 18:e277-e280 |
| McDevitt, Michael R; Thorek, Daniel L J; Hashimoto, Takeshi et al. (2018) Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. Nat Commun 9:1629 |
| Shah, Tariq; Krishnamachary, Balaji; Wildes, Flonne et al. (2018) Molecular causes of elevated phosphoethanolamine in breast and pancreatic cancer cells. NMR Biomed 31:e3936 |
| Chung, Liam; Thiele Orberg, Erik; Geis, Abby L et al. (2018) Bacteroides fragilis Toxin Coordinates a Pro-carcinogenic Inflammatory Cascade via Targeting of Colonic Epithelial Cells. Cell Host Microbe 23:203-214.e5 |
| LaFleur, Martin W; Muroyama, Yuki; Drake, Charles G et al. (2018) Inhibitors of the PD-1 Pathway in Tumor Therapy. J Immunol 200:375-383 |
| Handy, Catherine E; Antonarakis, Emmanuel S (2018) Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions. Future Oncol 14:907-917 |
| Popovic, Aleksandra; Jaffee, Elizabeth M; Zaidi, Neeha (2018) Emerging strategies for combination checkpoint modulators in cancer immunotherapy. J Clin Invest 128:3209-3218 |
Showing the most recent 10 out of 2393 publications
